

# PTC Therapeutics to Participate at Upcoming Virtual Investor Conference

November 16, 2021

SOUTH PLAINFIELD, N.J., Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET.

The presentation will be webcast live on the Events and Presentations page on the Investor section of PTC Therapeutics' website at <a href="https://ir.ptcbio.com/events-presentations">https://ir.ptcbio.com/events-presentations</a> and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

## About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at <a href="https://www.ptcbio.com">www.ptcbio.com</a> and follow us on Instagram, Facebook, Twitter, and LinkedIn.

## For More Information:

#### Investors:

Kylie O'Keefe +1 (908) 300-0691 kokeefe@ptcbio.com

#### Media:

Jeanine Clemente +1 (908) 912-9406 jclemente@ptcbio.com

View original content: <a href="https://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conference-301424417.html">https://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conference-301424417.html</a>

SOURCE PTC Therapeutics, Inc.